kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human IL-6 protein, 50µg  

Recombinant Human IL-6 protein, 50µg

Recombinant Human IL-6 Protein, Val 30 - Met 212, produced in human 293 cells (HEK293), Tag free, premium grade

Synonym: Recombinant Human Protein, IL6,HGF, Interleukin-6, BSF2, HSF, IFNB2

More details


Availability: within 7 days

455,00 €

Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells, to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.

Recombinant Human IL-6, premium grade(IL6-H4218) is expressed from human 293 cells (HEK293). It contains AA Val 30 - Met 212 (Accession # NP_000591).
Predicted N-terminus: Val 30
Human IL-6, premium grade (IL6-H4218), designed for preclinical stage, has the same activity and performance with GMP Human IL-6, which enables a seamless transition from preclinical development to clinical phases. Premium Grade product offer a cost efficient alternative of GMP Grade products for the early development phase when safety of raw materials is not top priority. By using Premium Grade products in early development phase, you can transition easily into clinical and commercial phase without need to revalidate the raw materials and modify manufacturing process.

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 20.8 kDa. The protein migrates as 23-29 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 0.01 EU per μg by the LAL method.

Host Cell Protein
<0.5 ng/μg of protein tested by ELISA.

Host Cell DNA
<0.02 ng/μg of protein tested by qPCR.

The sterility testing was performed by membrane filtration method.


>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Please refer to product data sheet.

Clinical and Translational Updates

(1) "JianPiYiShen formula prevents cisplatin-induced acute kidney injury in mice by improving necroptosis through MAPK pathway"
Li, He, Liu et al
BMC Complement Med Ther (2024) 24 (1), 101
(2) "Mediating effect of inflammation on the relationship between sleep disruption and suicidal ideation in major depressive disorder"
Zeng, Li, Chen et al
J Affect Disord (2024)
(3) "Evaluation of the effect of cannabidiol on the THLE-2 liver cell line exposed to lead"
Şahin, Azarkan, Türksoy
Sci Total Environ (2024)
Showing 1-3 of 191598 papers.